Charles Brynelsen was appointed as Chairman at Envoy Medical, Inc..
“Charles Brynelsen appointed as chairman of the board of directors”
Envoy Medical, Inc. — fact timeline
Source-grounded facts extracted from Envoy Medical, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Charles Brynelsen was elected as Director at Envoy Medical, Inc..
“each of Brent Lucas, Charles Brynelsen, Whitney Haring-Smith, Susan J. Kantor, Mona Patel, Janis Smith-Gomez and Glen A. Taylor were elected as directors”
David R. Wells was appointed as Chief Financial Officer at Envoy Medical, Inc..
“David R. Wells was appointed to serve as the Chief Financial Officer”
Brent Lucas was appointed as Chief Executive Officer at Envoy Medical, Inc..
“Brent Lucas was appointed to serve as the Chief Executive Officer”
Brent Lucas was elected as Director at Envoy Medical, Inc..
“each of Brent Lucas, Charles Brynelsen, Whitney Haring-Smith, Susan J. Kantor, Mona Patel, Janis Smith-Gomez and Glen A. Taylor were elected as directors”
Envoy Medical, Inc. shareholders approved Advisory Charter Proposals - six non-binding governance proposals at the 2023-09-27 meeting.
“Each of the Advisory Charter Proposals was approved. The votes for each sub-proposal were as follows: A. To change the total number of shares of all classes of authorized capital stock of the Company from 441,000,”
Envoy Medical, Inc. shareholders approved The Charter Proposal - approval of the Second Amended and Restated Certificate of Incorporation of New Envoy at the 2023-09-27 meeting.
“The Charter Proposal was approved by the Company’s stockholders, and received the following votes: Class of Common Stock For Against Abstain Class A Common Stock and Class B Common Stock, voting as a single class 12,845,753 288,246 0 Class A Common Stock, voting as a separate class 2,270,753 288,246 0 Class B Common Stock, voting as a separate class 10,575,000 0 0”
Envoy Medical, Inc. shareholders approved The Business Combination Proposal - approval of the Business Combination Agreement and the Business Combination at the 2023-09-27 meeting.
“The Business Combination Proposal was approved by the Company’s stockholders, and received the following votes: Class of Common Stock For Against Abstain Class A Common Stock and Class B Common Stock, voting as a single class 13,116,546 17,543 0”
Envoy Medical, Inc. entered into Business Combination Agreement with Anzu Special Acquisition Corp I, Envoy Merger Sub, Inc., and Envoy Medical Corporation valued at Aggregate Closing Merger Consideration of 15 million shares of Anzu Class A Common Stock (effective 2023-04-17).
“On April 17, 2023, Anzu Special Acquisition Corp I, a Delaware corporation (“ Anzu ”), entered into a business combination agreement (as it may be amended, supplemented or otherwise modified from time to time, the “ Business Combination Agreement ”), by and among Anzu, Envoy Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Anzu (“ Merger Sub ”), and Envoy Medical Corporation, a Minnesota corporation (“ Envoy ”).”
Envoy Medical, Inc. reported that prior financial statements should not be relied upon.
“On March 28, 2023, management and the audit committee (the “Audit Committee”) of the board of directors of Anzu Special Acquisition Corp I (the “Company”) concluded that the Company’s previously issued unaudited interim financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 (the “Q3 Form 10-Q” and such period, the “Affected Period”), should no longer be relied upon due to a reclassification of the extinguishment of a contingent liability and resulting restatement of the Company’s statements of operations, statements of changes in stockholders’ deficit and statements of cash flows for the Affected Period.”
Envoy Medical, Inc. shareholders rejected Adjournment Proposal: adjourn the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies at the 2023-02-28 meeting.
“Proposal No. 2 - The Adjournment Proposal – The stockholders approved a proposal to adjourn the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the Stockholder Meeting, there are insufficient shares Common Stock represented (either in person or by proxy) to constitute a quorum necessary to conduct business at the Special Meeting or at the time of the Special Meeting to approve the Extension Amendment Proposal or if the Maximum Redemption Condition (as defined in the Proxy Statement) is not met and is not waived by the Board in its sole discretion (the “ Adjournment Proposal ”). Passage of the Adjournment Proposal required a majority of the Company’s outstanding shares of Common Stock. The voting results were as follows: For Against Abstain 38,984,445 3,985,790 0 Although the Adjournment Proposal received sufficient votes to be approved, it was not presented for adoption and no mo”
Envoy Medical, Inc. shareholders approved Extension Amendment Proposal: amend the amended and restated certificate of incorporation to extend the date by which the Company has to consummate an initial business combination from March 4, 2023 to September 30, 2023 or such earlier date as determined by the Board at the 2023-02-28 meeting.
“Proposal No. 1 - The Extension Amendment Proposal – The stockholders approved a proposal to amend the Company’s amended and restated certificate of incorporation to extend the date by which the Company has to consummate an initial business combination from March 4, 2023 to September 30, 2023 or such earlier date as determined by the Board (the “ Extension Amendment Proposal ”). Passage of the Extension Amendment Proposal required approval by the affirmative vote of at least 65% of the Company’s issued and outstanding shares of Common Stock. The voting results were as follows: For Against Abstain 36,753,901 6,216,334 0”
Envoy Medical, Inc. entered into Extension Support Agreements with several unaffiliated third parties (Holders) valued at Sponsor agreed to transfer up to 80,000 Founder Shares per Holder for every 100,000 Public Shares re (effective 2023-02-23).
“On February 23, 2023, in connection with the special meeting of stockholders (the “ Special Meeting ”) of Anzu Special Acquisition Corp I, a Delaware corporation (the “ Company ”), to extend the date by which the Company has to consummate a business combination from March 4, 2023 to September 30, 2023 or such earlier date as determined by the Company’s board of directors (the “ Extension Amendment Proposal ”), the Company and Anzu SPAC GP I LLC (the “ Sponsor ”) entered into extension support agreements (the “ Extension Support Agreements ”) with several unaffiliated third parties (each, a “ Holder ”), pursuant to which each Holder agreed to (i) notify the Sponsor at least three business days prior to the Special Meeting regarding the number of shares of the Company’s Class A common stock (“ Public Shares ”) that such Holder intends to redeem and the number of Public Shares that such Holder intends to retain in connection with the Special Meeting and (ii) vote (and to cause its control”
Daniel J. Hirsch was appointed as Chief Financial Officer and Corporate Secretary at Envoy Medical, Inc..
“the Board appointed Mr. Hirsh as the Chief Financial Officer and Corporate Secretary of the Company.”
William Wulfsohn resigned as Chairman of the Board at Envoy Medical, Inc..
“On July 31, 2022, William Wulfsohn notified the Company of his resignation as a member of the Board effective immediately.”
Teresa A. Harris resigned as Director at Envoy Medical, Inc..
“On July 29, 2022, Teresa A. Harris notified the Company of her resignation as a member of the Board effective immediately.”
Peter J. Ganz resigned as General Counsel & Corporate Secretary at Envoy Medical, Inc..
“On July 29, 2022, Peter J. Ganz notified the Company of his resignation from his position as General Counsel & Corporate Secretary of the Company effective July 31, 2022.”
John W. Joy resigned as Chief Financial Officer at Envoy Medical, Inc..
“On July 29, 2022, John W. Joy notified the Company of his intention to resign from his position as Chief Financial Officer of the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.